Business Wire

JPND

10.1.2020 12:06:11 CET | Business Wire | Press release

Share
JPND Launches a New Call for Multinational Research on Novel Imaging and Brain Stimulation Methods and Technologies Related to Neurodegenerative Diseases

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has announced an €18 million transnational call for multinational research on novel imaging and brain stimulation methods and technologies for neurodegenerative diseases.

With neurodegenerative diseases on the rise and strongly linked to age, as many as 47 million people worldwide are estimated to be suffering from Alzheimer’s and related disorders today. This figure is expected to double every 20 years as the population ages. JPND was established in order to better coordinate research efforts across countries and disciplines to find causes more rapidly, develop cures and identify better ways to care for people with neurodegenerative diseases.

In recent years, major increases in the range and power of technologies across the basic, clinical and patient-centered domains of JPND have been seen. These include the use of imaging and analysis technologies, from Magnetic Resonance Imaging (MRI) to Position Emission Tomography (PET) to Molecular Imaging at both a molecular and a whole body imaging level, and the use of brain stimulation techniques such as Deep Brain Stimulation (DBS), Neuromodulation and Transcranial Magnetic Stimulation (TMS). Whilst techniques as such help to better understand, treat or diagnose neurodegenerative diseases, there is nevertheless a need to assess the potential of these approaches to deliver new and better treatment options for these debilitating diseases.

In this context, JPND is inviting multinational research teams to submit proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects aimed at the development of novel and the advanced use of existing cutting-edge imaging and brain stimulation technologies related to neurodegenerative diseases.

Professor Philippe Amouyel, University of Lille (France) and Chair of the JPND Management Board says: "The incredible progresses of brain imaging and brain stimulation during the last ten years, thanks to the development of new technologies, bioinformatics and artificial intelligence, offer new opportunities to better diagnose and alleviate the consequences of neurodegenerative diseases. For its 2020 transnational call, JPND has decided to support ambitious and innovative research projects that will take stock of these new approaches in a trans-disciplinary context. We hope that this highly competitive call will allow us to assess the potential of these approaches to deliver new and better treatment options.”

Proposals submitted under this call must focus on one or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, Prion diseases, Motor neuron diseases, Spinocerebellar ataxia (SCA), Huntington’s disease, Spinal muscular atrophy (SMA).

In addition, proposals must focus on one or several of the following research areas:

  • Imaging technologies
  • Development of novel imaging technologies
  • Improvements to the application of existing cutting-edge imaging technologies
  • Brain stimulation techniques
  • New or improved applications of both invasive and non invasive brain stimulation techniques for the diagnosis and treatment of neurodegenerative diseases

Pre-proposals must be submitted no later than 15:00h C.E.T. on March 6, 2020.

For more information about the call, please click here .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europcar Mobility Group Announces Exclusive Partnership With MIC Co., Ltd. to Expand Presence in Japan22.4.2026 09:02:00 CEST | Press release

Europcar Mobility Group has entered into an exclusive partnership agreement with MIC Co., Ltd., the operator of Japan’s extensive "Niconico Rent-A-Car" network. This landmark agreement marks Europcar Mobility Group’s first exclusive partnership in the Japanese market, aimed at providing seamless mobility solutions for the growing number of international travelers visiting the region. Enhancing possibilities for Inbound Travelers Since April 10, 2026, customers can book car rentals at Niconico Rent-A-Car’s directly-operated airport locations through Europcar’s global booking platform, allowing foreign travelers to arrange their transportation in Japan from overseas using a familiar interface, eliminating common booking hurdles and improving the overall travel experience.To date, the service is available across key gateway locations: Major Airports: Haneda, Narita, New Chitose, Fukuoka, Kagoshima, Nagasaki, and Kumamoto. Key Transit Hubs: Shin-Yokohama Station and Kansai Airport Rinku To

SkySparc Acquires Covarius and Uniun22.4.2026 09:00:00 CEST | Press release

SkySparc's OmniFi, Covarius and Uniun to anchor an expanded offering for corporate treasury clients SkySparc, a trusted global provider of digital transformation solutions for treasury and finance institutions, today announced the acquisition of Covarius Group Limited (“Covarius”) and Uniun Technology Limited (“Uniun”). The acquisitions accelerate SkySparc’s European expansion and deepen its specialist support for treasury transformation. Financial terms were not disclosed. Covarius and Uniun operate complementary businesses together enabling a more complete, end-to-end treasury solution. Covarius specialises in the implementation and optimisation of treasury management systems, underpinned by deep partnerships and a well-established global presence. Uniun adds a real-time, API-based integration platform focused on ERP-to-TMS connectivity and cash forecasting, supported by AI and data science. For clients, the combined proposition the two companies bring centres on improved cash visibi

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 07:30:00 CEST | Press release

An evolving macro-environment and a transitioning portfolio mix;Updated 2026 outlook Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivo

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 07:00:00 CEST | Press release

FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a serious condition with significant unmet medical need Designation supports enhanced regulatory interactions and alignment on efficient post-Phase 2a development strategies, including potential accelerated pathways 4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlight

LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 04:30:00 CEST | Press release

Recognised for its Media & Entertainment Industry Solutions and Infrastructure Modernization at Scale LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye